KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Research & Development: 2009-2024

Historic Research & Development for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $5.1 billion.

  • Regeneron Pharmaceuticals' Research & Development rose 16.00% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 billion, marking a year-over-year increase of 15.09%. This contributed to the annual value of $5.1 billion for FY2024, which is 15.61% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Research & Development of $5.1 billion as of FY2024, which was up 15.61% from $4.4 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Research & Development's 5-year high stood at $5.1 billion during FY2024, with a 5-year trough of $2.6 billion in FY2020.
  • Moreover, its 3-year median value for Research & Development was $4.4 billion (2023), whereas its average is $4.4 billion.
  • Data for Regeneron Pharmaceuticals' Research & Development shows a peak YoY grew of 25.61% (in 2022) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Research & Development (Yearly) stood at $2.6 billion in 2020, then increased by 8.05% to $2.9 billion in 2021, then grew by 25.61% to $3.6 billion in 2022, then increased by 23.56% to $4.4 billion in 2023, then increased by 15.61% to $5.1 billion in 2024.